Consolidation/Split - CHM
Filed with ASX · · 5 pages · English
Summary by 6ix AI
Chimeric Therapeutics Limited has announced a security consolidation. The consolidation will affect various types of securities, including ordinary shares and options. Trading in the post-consolidation securities is set to commence on a deferred settlement basis. The record date for the consolidation is specified, along with the timetable for the process. Further details regarding the consolidation are included in the announcement summary.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Chimeric Therapeutics Limited on 6ix
Earlier from Chimeric Therapeutics
- Chimeric receives $1.8 M advance on FY26 R&D tax incentive
- Half Year Report and Appendix 4D 31 December 2025
- Portfolio streamlined - return of CHM CLTX to City of Hope
- Funding and EGM update
- Quarterly Activities/Appendix 4C Cash Flow Report
Later from Chimeric Therapeutics
- Minaris Delivers 100% Manufacturing and Release Success for Chimeric Therapeutics' CDH17 Autologous CAR‑T Program
- CHM announces positive Phase 1/2 data at ASCO
- Appointment of Financial Adviser for Strategic Review
- CHM CDH17 Phase 1 clinical trial update - New DL 3 data
- Chimeric receives $1.62M advance on FY26 R&D tax incentive
Follow Chimeric Therapeutics into a list and get an email when it puts out news.
Follow Chimeric Therapeutics